Search Results
65 Results Found for “immunosuppression”
This issue of touchREVIEWS in Oncology & Haematology brings together a diverse collection of articles reflecting the growing complexity of cancer care and the continued evolution of precision medicine across tumour types. From rare malignancies and treatment-related challenges to emerging ...
An immunosuppressed person is one whose immune function is impaired by underlying disease and/or immunosuppressive medications, resulting in reduced immunosurveillance against malignant cells and increased vulnerability to opportunistic infections. Longstanding immunosuppression has been linked to increased risk for cutaneous (...
Small bowel adenocarcinoma (SBA) is a rare gastrointestinal malignancy, accounting for about 1–3% of gastrointestinal cancers.1,2 Its reported incidence has increased in recent decades, likely reflecting improved detection by balloon-assisted and capsule endoscopy and the more widespread use of cross-sectional imaging.3,4 ...
Immune checkpoint inhibitors (ICIs) act by blocking inhibitory pathways such as programmed cell death protein 1 (PD-1), programmed cell death ligand 1 (PD-L1)Â and cytotoxic T lymphocyte-associated antigen 4Â (CTLA-4), thereby restoring T-cell activity and promoting tumour cell destruction.1,2Â The ability of tumours ...
The first primary microangiopathic haemolytic anaemia was identified as thrombotic thrombocytopenic purpura (TTP) by Dr Moschowitz in 1924. At that time, the classic pentad of clinical features, still used today, included fever, erythrocyte fragmentation, thrombocytopenia, kidney injury and neurologic injury.1 It ...
The treatment of advanced or recurrent endometrial cancer has advanced significantly in recent years. This is particularly important, given the rising mortality rates of endometrial cancer, particularly among high-risk subtypes.1Â Platinum-based chemotherapy had long been the standard of care in ...
Mutations of the β-globin gene (HBB) cause sickle cell disease and β-thalassaemia, collectively named the β-haemoglobinopathies. As mankind’s most common severe genetic diseases, where they are most prevalent, public health systems can be stressed.1–3 Asymptomatic heterozygous carriers are protected ...
The management of children with diffuse midline gliomas (DMG) and other paediatric high-grade gliomas (pHGG) continue to present one of the most difficult challenges facing paediatric oncologists, characterized by poor patient outcomes.1Â Standard of care therapy, which includes a maximal ...
Multiple myeloma (MM) is the second most common haematological malignancy, with upwards of 35,000 diagnoses in the USA each year.1,2 It remains a leading cause of blood cancer-related mortality worldwide, and although therapeutic advances have allowed for significant improvements in the ...
Cancers of the anal canal are relatively uncommon, and account for less than 1% of all new cancer diagnoses in the UK.1 However, the incidence of these cancers has increased over the past decade, primarily in females, in which they have ...
Cumulatively, TNBC accounts for 35–40% of breast cancer deaths in the United States, despite only comprising 10–15% of total breast cancer cases diagnosed.1 Even before the use of anti-estrogen therapies became widespread, hormone receptor-positive breast cancer (HR+BC) provided a far more ...
Allogeneic haematopoietic stem cell transplant (allo-HSCT) remains a potential curative therapeutic option for patients with refractory/relapsed Hodgkin lymphoma (HL) in whom an autologous peripheral blood stem-cell transplantation (PBSCT) has failed. This is explained by the additional benefit of a ...
Allogeneic haematopoietic cell transplantation (allo-HCT) has a bi-faceted role in the treatment of haematopoietic malignancies. First, allo-HCT gives high-dose chemotherapy a chance to reduce the leukaemic burden; second, it allows graft-originated natural killer and T cells to initiate an adoptive ...
Prostate cancer is the second most common cause of cancer mortality in men, with most deaths occurring as a result of metastatic disease that has become resistant to androgen deprivation therapy (ADT).1Â Most recently, immunotherapy, in the form of immune ...
‘Attention is urgently required to protect cancer patients and preserve Europe’s healthcare professional, scientific and patient societies’ 17th March 2020 The Board of Directors of the European Cancer Organisation has released the following statement on the ongoing measures being taken ...
Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide, and a leading cause of cancer death.1 There were over 840,000 new cases in 2018, with the majority in Asia and almost half in China.2 The disease is asymptomatic in its early ...
At the ASCO 2019 annual meeting, Ramon Andrade de Mello discusses the promise of immunotherapies in oesophageal and gastric cancer. Highlighting the need to understand the tumor microenvironment to allow identification of biomarkers to appropriately select the best immune checkpoint inhibitors ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
